NASDAQ$HRMY

Harmony Biosciences Holdings Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Headline financials

Total Revenue

$56.3M

Previous: $6M+838.9%
EPS (adj)

$0.25

Previous: -$179.63+100.1%
Free Cash Flow

$10M

Previous: -$24M+141.8%
Net Income

-$206K

Previous: -$36.4M+99.4%
Operating Income

$7.76M

Previous: -$33.7M+123.0%
Gross Profit

$46.4M

Previous: $4.42M+949.6%
Cash & Equivalents

$229M

Previous: $24.5M+834.8%
Total Assets

$427M

Previous: $107M+300.2%
Stock-Based Comp

$2.82M

Previous: $8.4M-66.4%

Revenue & EPS history

Harmony Biosciences · Revenue · Quarterly

$56.3M

Q4 2020+838.9%vs Q4 2019
Beat estimate in 9 of 12 quarters(75%)
ActualEstimate

Revenue by segment

Harmony Biosciences · $56.3M total across 1 segment · Q4 2020

  • WAKIX Net Product Revenue
    $56.3M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+1.3%

Avg return

Earnings day

+3.0%

Avg return

5 days after

+6.0%

Avg return

30 days after

54%

14 / 26 earnings

Positive

+24.4%

Q3 2023

Best reaction

-15.1%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.1%-8.0%-1.8%
Q4 2025+2.6%+6.2%+2.1%
Q3 2025-1.6%-5.1%+18.1%
Q1 2025+7.0%+13.7%+16.9%
Q4 2024+8.2%-1.0%-2.4%
Q3 2024-5.5%-7.5%+0.0%
Q2 2024+8.5%+9.4%+15.0%
Q1 2024+3.5%+7.9%-1.3%
Q4 2023-1.5%+1.5%+0.9%
Q3 2023+24.4%+31.5%+47.4%
Q2 2023-7.9%-5.0%+2.5%
Q1 2023+9.9%+9.5%+5.0%
Q4 2022-6.1%-8.0%-15.2%
Q3 2022+12.5%+13.2%+15.4%
Q2 2022+6.3%+6.6%-7.8%
Q1 2022-15.1%-21.9%-5.0%
Q4 2021+5.6%+6.1%+31.5%
Q3 2021+0.1%-0.1%-9.3%
Q2 2021+13.9%+20.1%+41.4%
Q1 2021+1.2%+4.0%+21.8%
Q1 2020+1.2%+4.0%+21.8%
Q2 2020-4.1%+11.4%-2.1%
Q4 2020-4.1%+11.4%-2.1%
Q3 2020-6.8%-7.4%-12.0%
Q4 2019-6.8%-7.4%-12.0%
Q3 2019-6.8%-7.4%-12.0%
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro